Oncologia

Estudo randomizado | Eficácia de plinabulina vs. pegfilgrastima para prevenir neutropenia induzida por docetaxel em pacientes com tumores de órgãos sólidos.

21 Mar, 2022 | 16:01h

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial – JAMA Network Open

 

Comentário no Twitter

This RCT found that same-day plinabulin, a novel selective immunomodulating microtubule binding agent (SIMBA), is noninferior to next-day pegfilgrastim in chemotherapy-induced neutropenia prevention in patients receiving docetaxel chemotherapy. https://t.co/tUXuffISmB pic.twitter.com/LROsd3trPv

— JAMA Network Open (@JAMANetworkOpen) January 27, 2022

 

---

Plano de cuidado multidisciplinar do câncer de ovário em pacientes idosos.

21 Mar, 2022 | 15:59h

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement—A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO – Cancers

---

Estudo randomizado | Radioterapia de curto prazo com quimioterapia vs. quimiorradioterapia de longo prazo no câncer retal localmente avançado.

21 Mar, 2022 | 15:53h

Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) – Journal of Clinical Oncology

---

Resumo | Diretrizes alemãs baseadas em evidências sobre terapias focais no câncer de próstata localizado.

17 Mar, 2022 | 13:01h

German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy – Urologia Internationalis

---

Revisão | Visão geral e de mecanismos da toxicidade cardiovascular com inibidores de BRAF e MEK.

17 Mar, 2022 | 12:51h

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review

 

Comentário no Twitter

New #JACCCardioOnc issue is out!

BRAF/MEK inhibitors are associated w/ adverse CV effects including HTN, LV dysfunction, #VTE, atrial arrhythmias, & QT prolongation. Learn more in this state-of-the-art review: https://t.co/2r9L90DTmL#CardioOnc #CardioTwitter #Hypertension pic.twitter.com/Dz8i0sfBTU

— JACC Journals (@JACCJournals) March 15, 2022

 

---

Tendências de tumores associados ao HPV, características demográficas e vacinação nos EUA, 2001-2017.

17 Mar, 2022 | 12:46h

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Entrevista com o autor: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Conteúdos relacionados:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

---

Estudo de coorte | Incidência de doença cardiovascular entre adultos com câncer.

17 Mar, 2022 | 12:42h

Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study – JACC: CardioOncology

Comentários:

New Cancer Diagnosis May Up Risk for CV Death, Morbidity – HealthDay

What is the Incidence of CVD Among Adults With Cancer? – American College of Cardiology

 

Comentário no Twitter

A new cancer diagnosis may be independently associated with a "significantly higher risk" for cardiovascular death, #stroke, #HeartFailure, and pulmonary embolism, especially in the first year, according to a study in #JACCCardioOnc. https://t.co/XboZ2Ivsdl @JACCJournals

— American College of Cardiology (@ACCinTouch) March 16, 2022

 

---

Estudo de coorte | Radioterapia adjuvante vs. de salvamento precoce após prostatectomia para câncer de próstata pN1.

17 Mar, 2022 | 12:41h

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death – Journal of Clinical Oncology

Comentário: Adjuvant compared to early salvage therapy post prostatectomy in men with PN1 prostate cancer and decreased risk of mortality – Brigham and Women’s Hospital

---

Estudo randomizado | Toripalimabe com quimioterapia no carcinoma de esôfago de células escamosas avançado sem tratamento prévio.

17 Mar, 2022 | 12:38h

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial – Cancer Cell

 

Comentário no Twitter

Phase III JUPITER-03 trial testing addition of the anti-PD-1 mAb toripalimab to first-line chemotherapy for advanced-stage ESCC, mPFS was 5.7 vs 5.5 months, although 1-year PFS was 27.8% vs 6.1% (HR 0.58) and mOS was 17 vs 11 months (HR 0.58): https://t.co/jNSVzNiAzR #esocsm

— NatureRevClinOncol (@NatRevClinOncol) March 10, 2022

 

---

Revisão sistemática | Programas perioperatórios de recuperação melhorada (enhanced recovery after surgery) para mulheres com câncer ginecológico.

16 Mar, 2022 | 17:50h

Perioperative enhanced recovery programmes for women with gynaecological cancers – Cochrane Library

Ver também: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (algumas diretrizes têm acesso gratuito)

---